Medical oncologist to receive award for cancer drug development
Click Here to Manage Email Alerts
European Society for Medical Oncology will present Lillian L. Siu, MD, FRCPC, with the TAT 2020 Honorary Award.
The award recognizes Siu’s contributions to the development of anticancer therapies, particularly with regard to phase 1 trials of head and neck cancers.
Siu is senior medical oncologist, director of the phase 1 program, chair in precision genomics and clinical lead for the tumor immunotherapy program at Princess Margaret Cancer Centre. She also is professor of medicine at University of Toronto.
Siu will receive the award at ESMO Targeted Anticancer Therapies Congress, which will be held March 2-4 in Paris. She will deliver a keynote lecture at the congress titled “Rear view mirror and crystal ball of oncology drug development.”
The TAT Honorary Award acknowledges distinguished cancer drug development experts who have demonstrated commitment to the discovery and development of anticancer therapies.
“I am immensely honored to receive this award, which is particularly special to me as it recognizes my work in the field of early drug development as impactful for the community,” Siu said in an ESMO-issued press release. “The TAT Congress is a unique nexus that catalyzes advancements in oncological therapeutics by translating emerging knowledge in cancer biology and host immune system into clinical applications, and by incorporating technological advances to decode and characterize tumors and their microenvironment. With a growing armamentarium of anticancer agents, it is an exciting time to be an early drug developer.”